Floatz logo

Cabozantinib

Crohn Disease

National Cancer Institute (NCI)Small moleculePhase 1Active
CC
43/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
28/ 100
Competitive Position
95/ 100

Competitive context

9 Active assets in the Crohn Disease cohort.

Asset / SponsorPhaseRating
Dexasone
University of Saskatchewan
Phase 4BB
Epinephrine
Cedars-Sinai Medical Center
Phase 4BB
Marcaine
Cedars-Sinai Medical Center
Phase 4BB
Prucalopride
University of British Columbia
Phase 4BB
Hextend
Corewell Health West
Phase 3BB

View all 20 →

Same molecule, other indications

Cabozantinib is also rated in:

renal carcinomaActive
BB
Indicative · Phase 4
70 / 100
View asset →
castration-resistant prostate carcinomaActive
BB
Indicative · Phase 3
70 / 100
View asset →
kidney cancerActive
BB
Indicative · Phase 4
66 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →